EMA Withdrawn: Panretin (alitretinoin) — Eisai GmbH

View source ↗

Summary

The EMA has withdrawn Panretin (alitretinoin) from the European market, with Eisai GmbH as the marketing authorization holder, for indications related to sarcom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma
• Sarcoma

Drugs mentioned

• PANRETIN (ALITRETINOIN)

Snippet

Status: Withdrawn. Therapeutic area: Sarcoma, Kaposi. MAH: Eisai GmbH. Decision date: 24/01/2019